Clarus Therapeutics Holdings, Inc.
DelistedCIK 1817944fmd_11SNH82AX3JH77G13FXXGEVXC2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2022, 10 periods
Latest annual · FY2021
Millions- Total revenues
- 14
- Gross profit
- 11
- Operating income
- (40)
- Net income
- (41)
- Free cash flow
- (44)
Latest quarter · Q2 FY2022
Millions- Total revenues
- 4
- Gross profit
- 3
- Operating income
- (11)
- Net income
- (11)
- Free cash flow
- (18)
Clarus Therapeutics Holdings, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Revenue | $14 million | $6.4 million | +119.1% | 10-K 2022-03-31 · proof |
| Gross profit | $11.2 million | -$2.3 million | 10-K 2022-03-31 · proof | |
| Operating income | -$39.7 million | -$47.2 million | 10-K 2022-03-31 · proof | |
| Net income | -$40.6 million | $4.3 million | -1,034.8% | 10-K 2022-03-31 · proof |
| Cash from operating activities | -$43.8 million | -$41.6 million | 10-K 2022-03-31 · proof | |
| Free cash flow | -$43.8 million | -$41.6 million | 10-K 2022-03-31 · proof | |
| Total assets | $51.7 million | $19.4 million | +166.5% | 10-K 2022-03-31 · proof |
| Total liabilities | $67.6 million | $147 million | -54% | 10-K 2022-03-31 · proof |
| Cash and cash equivalents | $26.4 million | $7.2 million | +265.2% | 10-K 2022-03-31 · proof |
- What was Clarus Therapeutics Holdings, Inc.'s revenue in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported revenue of $14 million for fiscal 2021 (the year ended Dec 31, 2021), against $6.4 million the year before (+119.1%). Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What was Clarus Therapeutics Holdings, Inc.'s gross profit in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported gross profit of $11.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$2.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What was Clarus Therapeutics Holdings, Inc.'s operating income in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported operating income of -$39.7 million for fiscal 2021 (the year ended Dec 31, 2021), against -$47.2 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What was Clarus Therapeutics Holdings, Inc.'s net income in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported net income of -$40.6 million for fiscal 2021 (the year ended Dec 31, 2021), against $4.3 million the year before (-1,034.8%). Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What was Clarus Therapeutics Holdings, Inc.'s cash from operating activities in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported cash from operating activities of -$43.8 million for fiscal 2021 (the year ended Dec 31, 2021), against -$41.6 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What was Clarus Therapeutics Holdings, Inc.'s free cash flow in fiscal 2021?
- Clarus Therapeutics Holdings, Inc. reported free cash flow of -$43.8 million for fiscal 2021 (the year ended Dec 31, 2021), against -$41.6 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What are Clarus Therapeutics Holdings, Inc.'s total assets?
- As of Dec 31, 2021, Clarus Therapeutics Holdings, Inc. reported total assets of $51.7 million, against $19.4 million a year earlier (+166.5%). Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What are Clarus Therapeutics Holdings, Inc.'s total liabilities?
- As of Dec 31, 2021, Clarus Therapeutics Holdings, Inc. reported total liabilities of $67.6 million, against $147 million a year earlier (-54%). Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
- What are Clarus Therapeutics Holdings, Inc.'s cash and cash equivalents?
- As of Dec 31, 2021, Clarus Therapeutics Holdings, Inc. reported cash and cash equivalents of $26.4 million, against $7.2 million a year earlier (+265.2%). Source: the 10-K filed with the SEC on Mar 31, 2022. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1817944&period_type=annual&limit=5"Information only, not investment advice.